	US 12,296,005 B2
	Hepatitis C virus immunogenic compositions and methods of use thereof
Michael Houghton, Danville, CA (US); Abdolamir Landi, Edmonton (CA); Michael Logan, Edmonton (CA); John L. Law, Edmonton (CA); Darren Hockman, Edmonton (CA); and Chao Chen, Edmonton (CA)
Assigned to The Governors of the University of Alberta, Edmonton (CA)
Filed by The Governors of the University of Alberta, Edmonton (CA)
Filed on Oct. 26, 2021, as Appl. No. 17/511,177.
Application 17/511,177 is a continuation of application No. 16/334,683, granted, now 11,324,818, previously published as PCT/IB2017/055714, filed on Sep. 21, 2017.
Claims priority of provisional application 62/397,763, filed on Sep. 21, 2016.
Prior Publication US 2022/0105175 A1, Apr. 7, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/29 (2006.01); A61K 39/00 (2006.01); A61K 39/12 (2006.01); A61K 39/39 (2006.01); A61P 31/14 (2006.01)

CPC A61K 39/29 (2013.01) [A61K 39/12 (2013.01); A61K 2039/53 (2013.01); A61K 2039/54 (2013.01); A61K 2039/55544 (2013.01); A61K 2039/70 (2013.01); C12N 2710/10034 (2013.01); C12N 2710/10043 (2013.01); C12N 2710/24134 (2013.01); C12N 2710/24143 (2013.01); C12N 2770/24234 (2013.01)]

17 Claims

1. An immunogenic composition comprising as separate entities:

a) one or more nucleic acids comprising nucleotide sequences encoding a hepatitis C virus (HCV) E1/E2 heterodimeric polypeptide comprising:

i) an HCV E1 polypeptide; and

ii) an HCV E2 polypeptide;

b) a nucleic acid comprising a nucleotide sequence encoding a T-cell epitope polypeptide comprising a T-cell epitope present in an HCV protein other than E1 and E2,

wherein the T-cell epitope polypeptide comprises an amino acid sequence having at least 20% amino acid sequence identity to the amino acid sequence of one of:

a) a TP29 polypeptide comprising the amino acid sequence set forth in SEQ ID NO:94, wherein the T-cell epitope polypeptide has a length of 25 amino acids to 35 amino acids;

b) a TP50 polypeptide comprising the amino acid sequence set forth in SEQ ID NO:99;

c) a TP52 polypeptide comprising the amino acid sequence set forth in SEQ ID NO:95;

d) a TP70 polypeptide comprising the amino acid sequence set forth in SEQ ID NO:96;

e) a TP100 polypeptide comprising the amino acid sequence set forth in SEQ ID NO:97

f) a TP171 polypeptide comprising the amino acid sequence set forth in SEQ ID NO:89;

g) a TP228 polypeptide comprising the amino acid sequence set forth in SEQ ID NO:81;

h) a TP553 polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 100;

i) a TP778 polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 101; and

j) a TP1985 polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 102; and

c) a pharmaceutically acceptable carrier.